Houghton J A, Williams L G, Radparvar S, Houghton P J
Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
Cancer Res. 1988 Jun 1;48(11):3062-9.
The method for measuring polyglutamate forms of CH2-H4PteGlu and H4PteGlu, by entrapment in ternary complexes with [6-3H]5-fluoro-2'-deoxyuridylate and Lactobacillus casei thymidylate synthase has been characterized. Results demonstrated that (a) the relationship between concentration of CH2-H4PteGlu and complex isolated on nondenaturing gels was dependent upon the number of glutamyl residues, and an alternative method for data analysis has been presented, (b) the relationship was linear over a 100-fold change in concentration, (c) formation of isolatable complex was time dependent, (d) noncovalent complexes formed with PteGlu2-5 could be isolated only at concentrations considerably higher than those required for CH2-H4PteGlu1-6, and (e) endogenous deoxyuridylate would be unlikely to interfere significantly with the assay. The distribution of polyglutamates of CH2-H4PteGlu and the combined pools of CH2-H4PteGlu plus H4PteGlu were subsequently examined in three human colon adenocarcinoma xenografts. In each tumor, the pentaglutamate of CH2-H4PteGlu and H4PteGlu was the most prominent species, followed by the hexaglutamate, constituting 68 to 92% of the CH2-H4PteGlu pool, and greater than 93% of the combined pools. A small percentage of di-, tri-, and tetraglutamates were also detected. Using a catalytic assay, the combined pool of CH2-H4PteGlu and H4PteGlu was estimated in the range of 0.5 to 2.7 microM in cell water, and for CH2-H4PteGlu, from 185 nM to 1.7 microM. Using thymidylate synthase purified from colon adenocarcinoma HxVRC5, CH2-H4PteGlu5 (where the subscript digit attached to the glutamate portion equals the number of glutamate residues) stabilized the covalent ternary complex at greater than 200-fold lower concentration in comparison to CH2-H4PteGlu1. Data indicated that in each colon tumor, the concentrations of CH2-H4PteGlun or CH2-H4PteGlun plus H4PteGlun were suboptimal for the interaction of 5-fluoro-2'-deoxyuridylate with thymidylate synthase, and would predict for relatively transient inhibition of thymidylate synthase after treatment with 5-fluorouracil. These data support therapeutic modulation to increase the concentration of CH2-H4PteGlun in the treatment of colon adenocarcinomas with 5-fluorouracil.
通过与[6-³H]5-氟-2'-脱氧尿苷酸和干酪乳杆菌胸苷酸合酶形成三元复合物来捕获CH2-H4PteGlu和H4PteGlu的聚谷氨酸形式的方法已得到表征。结果表明:(a) CH2-H4PteGlu浓度与在非变性凝胶上分离的复合物之间的关系取决于谷氨酰残基的数量,并提出了一种数据分析的替代方法;(b) 该关系在浓度变化100倍范围内呈线性;(c) 可分离复合物的形成与时间有关;(d) 仅在浓度远高于CH2-H4PteGlu1-6所需浓度时才能分离出与PteGlu2-5形成的非共价复合物;(e) 内源性脱氧尿苷酸不太可能对该测定产生显著干扰。随后在三个人类结肠腺癌异种移植瘤中检测了CH2-H4PteGlu的聚谷氨酸分布以及CH2-H4PteGlu与H4PteGlu的合并库。在每个肿瘤中,CH2-H4PteGlu和H4PteGlu的五聚谷氨酸是最主要的形式,其次是六聚谷氨酸,占CH2-H4PteGlu库的68%至92%,占合并库的93%以上。还检测到少量的二聚、三聚和四聚谷氨酸。使用催化测定法,估计细胞内水中CH2-H4PteGlu和H4PteGlu的合并库在0.5至2.7微摩尔范围内,CH2-H4PteGlu为185纳摩尔至1.7微摩尔。使用从结肠腺癌HxVRC5中纯化的胸苷酸合酶,与CH2-H4PteGlu1相比,CH2-H4PteGlu5(其中连接到谷氨酸部分的下标数字等于谷氨酸残基的数量)在浓度低200倍以上时稳定共价三元复合物。数据表明,在每个结肠肿瘤中,CH2-H4PteGlun或CH2-H4PteGlun加H4PteGlun的浓度对于5-氟-2'-脱氧尿苷酸与胸苷酸合酶的相互作用而言并非最佳,并且可以预测在用5-氟尿嘧啶治疗后胸苷酸合酶的抑制作用相对短暂。这些数据支持在使用5-氟尿嘧啶治疗结肠腺癌时进行治疗调节以增加CH2-H4PteGlun的浓度。